The price trend for Novartis (NVS) has been bearish lately and the stock has lost 5.1% over the past two weeks. However, the formation of a hammer chart pattern in its last trading session indicates ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find ...

Investors in Novartis (Symbol: NVS) saw new options begin trading today, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVS options chain ...

Novartis (NYSE:NVS – Get Free Report) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Saturday. NVS has been the topic of a number of ...

Novartis (NVS) is acquiring Avidity Biosciences (RNA) for $12 billion to offset looming patent expirations and drive near-term growth with late-stage rare disease assets. The acquisition is expected ...

Novartis delivered strong Q2 results with 24% net income growth and robust sales from key drugs like Kisqali and Pluvicto, supporting our positive outlook. Despite generic competition and tariff ...